Immune evasion of tumor cells using membrane-bound complement regulatory proteins (Q33774245)

29 July 2017

1 reference

title

Immune evasion of tumor cells using membrane-bound complement regulatory proteins (English)

1 reference

evasion of host immune response

29 July 2017

1 reference

Gorter A

1

1 reference

PubMed ID

10562709

29 July 2017

Meri S

series ordinal

2

1 reference

29 July 2017

1 December 1999

1 reference

29 July 2017

1 reference

29 July 2017

20

1 reference

29 July 2017

12

1 reference

29 July 2017

576-582

1 reference

Control of the complement system.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Cytolysis of nucleated cells by complement: cell death displays multi-hit characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

C5A anaphylatoxin and its seven transmembrane-segment receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Identification of an additional class of C3-binding membrane proteins of human peripheral blood leukocytes and cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Protection of thyroid cancer cells by complement-regulatory factors

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Complement-regulatory proteins in ovarian malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Distribution of complement regulators (CD46, CD55 and CD59) in skin appendages, and in benign and malignant skin neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Expression and function of CD59 on colonic adenocarcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Purification and functional properties of soluble forms of membrane cofactor protein (CD46) of complement: identification of forms increased in cancer patients' sera

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Soluble CD59 in pregnancy and infancy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

A functional analysis of recombinant soluble CD46 in vivo and a comparison with recombinant soluble forms of CD55 and CD35 in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Tumor heterogeneity and immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Augmented lung adenocarcinoma cytotoxicity by the combination of a genetically modified anti-Lewis Y antibody and antibodies to complement regulatory proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Response of SCC-12F, a human squamous cell carcinoma cell line, to complement attack

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Mechanisms of complement resistance induced by non-lethal complement attack and by growth arrest

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Role of Fc gamma receptors in cancer and infectious disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Activation of human complement by mouse and mouse/human chimeric monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Divergent roles for Fc receptors and complement in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Mechanisms of in vivo anti-neuroblastoma activity of human natural IgM

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Mapping the regions of the complement inhibitor CD59 responsible for its species selective activity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Complement killing of human neuroblastoma cells: a cytotoxic monoclonal antibody and its F(ab')2-cobra venom factor conjugate are equally cytotoxic

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Additive cytotoxicity of different monoclonal antibody-cobra venom factor conjugates for human neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Urinary excretion of protectin (CD59), complement SC5b-9 and cytokines in membranous glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

The influence of tumour necrosis factor-alpha, interleukin-1 beta and interferon-gamma on the expression and function of the complement regulatory protein CD59 on the human colonic adenocarcinoma cell line HT29.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Tumour necrosis factor-alpha up-regulates decay-accelerating factor gene expression in human intestinal epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Lack of effect of different cytokines on expression of membrane-bound regulators of complement activity on human uveal melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Down-regulation of CD59 (protectin) expression on human colorectal adenocarcinoma cell lines by levamisole

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

Complement activation and regulator expression after anoxic injury of human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5699%2899%2901537-6

7 January 2021

10.1016/S0167-5699(99)01537-6

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10562709